Rinvoq vs Otezla
A side-by-side look at two autoimmune medications advertised on TV. Informational only — not medical advice.
| US Rinvoq | US Otezla | |
|---|---|---|
| Generic name | upadacitinib | apremilast |
| Drug class | JAK Inhibitor | PDE4 Inhibitor |
| Treats | Rheumatoid arthritis, psoriatic arthritis, eczema | Plaque psoriasis, psoriatic arthritis, Behçet's disease |
| Category | Autoimmune | Autoimmune |
| Manufacturer | AbbVie | Amgen |
| Year approved | 2019 | 2014 |
| FDA warning | Black box warning | No boxed warning |
| Est. TV ad spend | $175M | $110M |
| Common side effects | Serious infections, Blood clots, Cardiovascular events, Cancer risk | Diarrhea, Nausea, Headache, Weight loss |
Frequently asked questions
Is Rinvoq or Otezla better?
Neither is universally "better." Rinvoq (upadacitinib) and Otezla (apremilast) are both used for autoimmune, but the right choice depends on your medical history, insurance and your doctor's guidance. This comparison is informational only.
What's the difference between Rinvoq and Otezla?
Rinvoq is a JAK Inhibitor made by AbbVie, while Otezla is a PDE4 Inhibitor made by Amgen. See the table above for a side-by-side breakdown.
Which one spends more on TV ads?
Rinvoq has the larger estimated TV advertising budget of the two.